COMMUNIQUÉS West-GlobeNewswire

Microbot Medical® Commences Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System in the U.S. at the Society of Interventional Radiology (SIR) Annual Scientific Meeting
13/04/2026
Successful Execution of the Limited Market Release (LMR) Includes Adoption by Globally Recognized Healthcare Systems in the U.S. Market and Demonstrates Broad Market Scalability in Key Endovascular Procedures HINGHAM, [...]
Heartflow Files Patent Infringement Lawsuit Against Cleerly
13/04/2026
Heartflow asserts that Cleerly infringed foundational patented technology central to the Heartflow Platform MOUNTAIN VIEW, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the [...]
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer
13/04/2026
- Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE [...]
Chemed Corporation Announces a Five-Year $450 Million Amended and Restated Credit Agreement
13/04/2026
CINCINNATI, April 13, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation ("Chemed") (NYSE:CHE) announced that it has entered into an Amended and Restated Credit Agreement for its Credit Facility (“Credit Agreement”). JPMorgan [...]
Nanox Signs Distribution Agreement with Digital X-Ray Imaging to Expand Nanox.ARC Adoption in Arkansas
13/04/2026
Fourth distribution agreement of 2026 strengthens Nanox’s U.S. commercial momentum PETACH TIKVA, Israel, April 13, 2026 (GLOBE NEWSWIRE) -- Nano X Imaging Ltd. (NASDAQ NNOX), a leader in innovative medical imaging [...]
Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary
13/04/2026
Tim is a seasoned legal executive bringing extensive experience supporting commercial biopharmaceutical companies FOSTER CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial- [...]
Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures
13/04/2026
-- Select findings demonstrate that the use of EXPAREL ® (bupivacaine liposome injectable suspension) in outpatient Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA) is associated with lower total [...]
Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism
13/04/2026
Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-479 in Healthy Volunteers Data Anticipated in Late 2026 or Early 2027 SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE [...]
Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference
13/04/2026
-Trial Combines LIXTE’s LB-100 with Dostarlimab; Results Give Patients New Hope for a Challenging Disease with Limited Therapeutic Options- BOCA RATON, Fla., April 13, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology [...]
Stryker signs definitive agreement to acquire Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio
13/04/2026
Portage, Michigan, April 13, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced that it has signed a definitive agreement to acquire Amplitude Vascular Systems, Inc. (AVS), a [...]
BrainsWay to Participate in the 25th Annual Needham Virtual Healthcare Conference
13/04/2026
BURLINGTON, Mass. and JERUSALEM, April 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental [...]
Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences
13/04/2026
VICTORIA, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
CVRx Reports Preliminary First Quarter 2026 Financial Results
13/04/2026
Delivered strong topline performance with first quarter revenue expected to be $14.7 million to $14.8 million, approximately 20% growth compared to first quarter of 2025 Early data in 2026 shows an increase in the 30- [...]
Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer
13/04/2026
Trial met all primary and key secondary endpoints, including progression-free survival and overall survival Company intends to include these data in a future New Drug Application submission to the U.S. Food and Drug [...]
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
13/04/2026
AKB-9090 is being evaluated as a potential treatment for cardiac surgery-associated acute kidney injury CAMBRIDGE, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a [...]
Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026
13/04/2026
Essential3 is the first positive Phase 3 program in essential tremor; ulixacaltamide has received FDA Breakthrough Therapy Designation, with data selected for plenary presentation at AAN 2026 Praxis to present 3 oral [...]
Catheter Precision Announces Accepted Publication in Leading European Medical Journal
13/04/2026
Clinical Evidence Further Demonstrates Efficacy and Accuracy of VIVO for Ventricular Procedures FORT MILL, S.C., April 13, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK) (“VTAK” or the “Company [...]
ImPact Biotech Presents Preliminary Data from Phase 1 Study of Padeliporfin VTP in LA-PDAC at SIR 2026 and Provides Strategic Business Update
13/04/2026
– Initial data from first cohort in LA-PDAC show 66% (2/3) patients resected following VTP at lowest light dose with a consistent and well-tolerated safety profile – – LA-PDAC program represents large market opportunity [...]
Veld Pharmaceuticals GmbH Announces Collaboration with Chiesi Farmaceutici S.p.A to Expand Access to Rare Disease Therapies Across Africa
13/04/2026
Managed Access Program to support physician-led access to nine rare-disease therapies in accordance with local regulatory frameworks ZUG, Switzerland, April 13, 2026 (GLOBE NEWSWIRE) -- Veld Pharmaceuticals GmbH (“Veld [...]

Pages